Dare Bioscience (DARE) Earns “Buy” Rating from Maxim Group

Share on StockTwits

Maxim Group reissued their buy rating on shares of Dare Bioscience (NASDAQ:DARE) in a research report report published on Thursday, AnalystRatings.com reports. They currently have a $3.00 price target on the biotechnology company’s stock.

“Daré reported 1Q19 with a net loss of ($3M). The company ended the period with $3.5M in cash, though this does not include a $5.2M capital raise (5.26M shares, no warrants) from April. Including the raise, the company has runway until ~1Q20, through multiple catalysts including data from the Post-Coital Test for Ovaprene.”,” the firm’s analyst wrote.

NASDAQ:DARE opened at $0.89 on Thursday. Dare Bioscience has a 1 year low of $0.60 and a 1 year high of $3.25. The company has a market capitalization of $10.18 million, a PE ratio of -0.82 and a beta of 2.20.

In other news, Director Roger Hawley bought 454,545 shares of the business’s stock in a transaction dated Thursday, April 11th. The stock was bought at an average price of $1.10 per share, for a total transaction of $499,999.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 19.00% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its position in Dare Bioscience by 33.5% in the 1st quarter. Renaissance Technologies LLC now owns 178,346 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 44,800 shares during the last quarter. Jane Street Group LLC bought a new position in Dare Bioscience in the 1st quarter worth approximately $65,000. Finally, Geode Capital Management LLC raised its position in Dare Bioscience by 80.9% in the 4th quarter. Geode Capital Management LLC now owns 105,470 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 47,170 shares during the last quarter. Hedge funds and other institutional investors own 6.23% of the company’s stock.

Dare Bioscience Company Profile

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

Recommended Story: Price to Earnings Ratio (PE)

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

China Shenhua Energy –  to Issue $0.42 Annual Dividend
China Shenhua Energy – to Issue $0.42 Annual Dividend
Wall Financial Co.  Plans Dividend Increase – $2.00 Per Share
Wall Financial Co. Plans Dividend Increase – $2.00 Per Share
Guaranty Bancshares, Inc.  Declares Quarterly Dividend of $0.17
Guaranty Bancshares, Inc. Declares Quarterly Dividend of $0.17
Bancolombia SA  To Go Ex-Dividend on June 26th
Bancolombia SA To Go Ex-Dividend on June 26th
Vail Resorts, Inc.  Announces $1.76 Quarterly Dividend
Vail Resorts, Inc. Announces $1.76 Quarterly Dividend
Dynex Capital Inc Announces Monthly Dividend of $0.18
Dynex Capital Inc Announces Monthly Dividend of $0.18


© 2006-2019 Ticker Report